Sanofi Emcure in pact to market oncology drugs
06 August 2014
Sanofi India today said that it had entered into a marketing and distribution agreement with Emcure Pharmaceuticals (Emcure) for its oncology portfolio in India.
According to the agreement, while Sanofi will continue to own its oncology range comprising four brands - Taxotere, Jevtana, Fludara and Fasturtec.
Emcure will market and distribute these brands through its Specialty Unit.
Commenting on the partnership, Dr Shailesh Ayyangar, vice president, South Asia and managing director, Sanofi India Limited and Sanofi – Synthelabo (India) Limited said ''Sanofi is highly committed to the field of Oncology."
Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies.
Doctors and patients will now have access - 'under one roof' - to one of the most comprehensive and complementing Oncology portfolios in India. Sanofi will continue to provide strong scientific and medical support to Emcure's already well-established and fast growing Oncology business.''
Satish Mehta, managing director, Emcure Pharmaceuticals said, ''We are delighted to be identified as the partner-of-choice by Sanofi in India; and for being entrusted with such a prestigious global oncology portfolio. We believe that the coming together of Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us to provide an even wider array of value driven healthcare solutions. We are extremely optimistic about its prospects and committed to creating a long-term partnership with Sanofi.''